For years, researchers have been moving towards decentralized clinical trials (DCTs), and in a matter of months, COVID-19 changed the trajectory. Clinical operations teams and investigator sites around the world rose to the challenge and worked quickly to deploy new tactics to serve their study participants. The resulting reward is that DCTs, which can be leveraged smartly to reduce participant burden and improve recruitment and retention, are now becoming more widely adopted in design considerations. But rewards bring about new risks and challenges, and DCTs create new concerns for monitoring participant safety. Dario Lirio – Senior Director, LifeSphere Clinical at ArisGlobal – analyzes the risks and rewards of DCTs.
The Prescriber in 2022: Engaging HCPs in the COVID-Endemic EraBrands, Consumers, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), Drug Delivery, Endemic, Europe, HCPs, Medical Devices, Mobile, Pharma, Physicians, Prescribers, Reports, Research, Telehealth, United States
Of all the communities touched by the COVID-19 pandemic, healthcare professionals (HCPs) are arguably among those most affected. Specialists on the front lines in primary care, critical care, infectious diseases, and pulmonology roles have experienced COVID-19 first hand—often risking their own health and that of their families to help. A new report from Apollo Intelligence provides a barometer on physicians’ sentiments for 2022, and together with other research, frames a wake-up call to medical device and pharma teams in charge of building a brand presence with prescribers.
For the first time ever, Klick Health took its in-office flu shot clinic on the road in keeping with the company’s people-first culture and commitment to help keep team members and their families healthy and happy.
Tesla, the electric car company founded and run by Elon Musk, is building mobile molecular printers to assist Germany’s CureVac in manufacturing an experimental COVID-19 vaccine.
Switzerland will introduce a monitoring system to assuage concerns about the potential health impact of fifth-generation (5G) mobile frequency emissions and smooth the cutting-edge technology’s rollout, the government said.
Introducing mobile into the patient engagement journey is one way that brands can drive efficiencies across three key areas.
More time is now spent on the Internet through smartphones than on PCs; that includes both work and leisure time. But it’s not necessarily easier to connect with your customers – in fact, the opposite is often the case. The problem, according to Nielsen and other sources, is that 86 percent of mobile usage is through mobile apps, with the mobile web representing only 14 percent.
A review about two promising applications of digital data to improve patient marketing, plus a third “low-hanging fruit” tactic most brands should explore.